Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

## Patient: Patient, Example

DOB
Gender:
Patient Identifiers:
Female
01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

## Porphyrins and Porphobilinogen (PBG), Urine

ARUP test code 2002181

| Hours Collected | Not Provided hr <br> Per 24 h calculations are provided to aid interpretation for collections with a duration of 24 hours and an average daily urine volume. For specimens with notable deviations in collection time or volume, ratios of analytes to a corresponding urine creatinine concentration may assist in result interpretation. |
| :---: | :---: |
| Total Volume | Not Provided mL |
| Creatinine, Urine - per volume | $37 \mathrm{mg} / \mathrm{dL}$ |
| Creatinine, Urine - per 24h | Not Applicable mg/d (Ref Interval: 500-1400) |
| Uroporphyrin - ratio to CRT | 340 umol/mol CRT H (Ref Interval: 0-4) |
| Heptacarboxylate - ratio to CRT | 121 umol/mol CRT H (Ref Interval: 0-2) |
| Coproporphyrin I - ratio to CRT | 8 umol/mol CRT H (Ref Interval: 0-6) |
| Coproporphyrin III - ratio to CRT | 36 umol/mol CRT H (Ref Interval: 0-14) |
| Porphyrin Urine Interpretation | See Note |
|  | Elevated concentrations of urine uroporphyrin and heptacarboxyl, hexacarboxy 1 , and pentacarboxy 1 porphyrins in a pattern consistent with porphyria cutanea tarda (PCT). Concentrations of uroporphyrin and heptacarboxy 1 porphyrin greater than 40 micromoles per mole of creatinine are typically associated with cutaneous photosensitivity. <br> INTERPRETIVE INFORMATION: Porphyrins, Fractionation and Quantitation, <br> Results are normalized to creatinine concentration and reported |


|  | as a ratio of amounts (micromoles of porphyrin/moles of creatinine). <br> This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. |
| :---: | :---: |
| Porphobilinogen (PBG), Urine -per volume | < 5 umol/L (Ref Interval: 0.0-8.8) <br> INTERPRETIVE INFORMATION: Porphobilinogen (PBG), urine - per volume <br> This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. |
| Porphobilinogen (PBG), Urine -per 24h | Not Applicable umol/d (Ref Interval: 0.0-11.0) |


| VERIFIED/REPORTED DATES |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Procedure | Accession | Collected | Received | Verified/Reported |
| Hours Collected | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Total Volume | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Creatinine, Urine - per volume | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Creatinine, Urine - per 24 h | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Uroporphyrin - ratio to CRT | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Heptacarboxylate - ratio to CRT | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Coproporphyrin I - ratio to CRT | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Coproporphyrin III - ratio to CRT | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Porphyrin Urine Interpretation | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Porphobilinogen (PBG), Urine -per volume | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Porphobilinogen (PBG), Urine -per 24 h | 23-261-109433 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |

## END OF CHART

